TABLE 1.

Clinical data for patients with candidemia who responded to therapy with fluconazole

Patient	Age (yr)	Critically illa	Cancer	Trans- plant	Neutro- peniab	Candida sp.	24-h MIC (μg/ml)	48-h MIC (μg/ml)	Daily fluconazole dosage (mg)	24-h dose/ MIC ratio	48-h dose/ MIC ratio
5	33	No	None	No	No	C. albicans	0.25	0.5	400	1,600	800
9	73	No	Solid	No	No	C. albicans	0.25	0.5	200	800	400
15	55	No	AMLc	No	Yes	C. tropicalis	0.25	0.5	200	800	400
2	50	No	Ovary	No	No	C. albicans	0.25	0.25	200	800	800
10	18	Yes	None	No	No	C. albicans	0.25	0.25	200	800	800
1	66	No	AML	No	Yes	C. albicans	0.5	0.5	200	400	400
8	67	No	Solid	No	No	C. lusitaniae	0.25	0.25	100	400	400
12	25	No	None	No	No	C. albicans	0.5	0.5	200	400	400
13	76	Yes	None	No	No	C. parapsilosis	1	2	200	200	100
3	65	No	Colon	No	No	C. albicans	0.5	0.5	100	200	200
7	47	Yes	None	No	No	C. albicans	1	1	200	200	200
4	64	No	Multiple myeloma	No	No	C. tropicalis	4	4	400	100	100
11	30	No	AML	No	Yes	C. parapsilosis	4	4	400	100	100
14	25	No	Neuroblastoma	No	No	C. glabrata	2	2	200	100	100
6	70	Yes	Lymphoma	No	No	C. glabrata	8	32	200	25	6.25

^aCritically ill, Pitt bacteremia score ≥4 (18).

^bNeutropenia, absolute neutrophil count <1,000 cells/mm³.

^cAML, acute myelogenous leukemia.